Webinar: Avoiding Common Pitfalls in Cell and Gene Therapy Trials
Medpace’s Regulatory Submissions Manager, Jan Ohotski, and Clinical Trial Manager, Elizabeth Shepherd, discuss how to operationalize advance therapy clinical trials using hard-won lessons learned from…
[Presentation] How the COVID-19 Pandemic Impacted Clinical Development from an Operations Perspective
Medpace’s Director of Clinical Trial Management, Alex Krutilin, took the virtual stage at the Outsourcing in Clinical Trials UK & Ireland conference to discuss how…
A New Paradigm in Infectious Diseases Treatment & Prophylaxis Shaped by the Current Pandemic
The COVID-19 pandemic will end, or as any pandemic in the past, will lose its momentum. Yet, the precedents and the new paradigms formed in…
Webinar: Revisiting and Rebuilding Clinical Development of Drugs for Antimicrobial Resistance – Lessons Learned During the COVID-19 Pandemic
Join AMR experts from Medpace, IHMA, and GARDP as they discuss how we can use the momentum from the pandemic to rethink, rebuild and revitalize…
Chronic Kidney Disease & Its Impact on Clinical Development – Part 2
This post is the second of a three-part blog series. In Part 2, we take a look at the biomarkers for chronic kidney disease.
Wearable Biosensors are Changing the Future of Clinical Trials
Clinical trialists have moved to an older trial model requiring less patient mobility and preferably centered at home, but now with innovative next-gen remote biosensing…
Partnership with Greenleaf Enhances Strategic Regulatory Affairs Capabilities
"This partnership strengthens our global Regulatory Affairs offering and allows us to expand our strategic capabilities to support our Sponsors’ programs.” - Jon Isaacsohn, MD,…
Chronic Kidney Disease & Its Impact on Clinical Development – Part 1
Recently, medical and operational experts from our nephrology team presented a webinar on Chronic Kidney Disease (CKD). Over the next several weeks, we will build…
Medpace Clinical Pharmacology Unit working with HiFiBIO Therapeutics on a SARS-CoV-2 ID-neutralizing antibody for the treatment and prevention of COV19
In a recent news release, HiFiBiO Therapeutics announced the successful completion of the first cohort of the Phase I study (NCT04590430) of HFB30132 which was…
New White Paper: The Intersection of Rare Diseases and Advanced Therapies and What it Means for Clinical Development
Read the press release for the latest whitepaper on advanced therapies and rare diseases published by Xtalks and Medpace.